Advicenne publishes its half-year 2021 financial results

PARIS–(COMMERCIAL THREAD) – Regulatory news:

Advicenne (Paris: ADVIC) (ESB: ADVIC) (Euronext: ADVIC), a specialist pharmaceutical company dedicated to the development and commercialization of innovative treatments for people with rare kidney diseases, today announces the publication of its half-year financial results ending June 30, 2021.

Key events – First half of 2021

On Sibnayal â„¢ / ADV 7103, Advicenne main product

  • Received clearance from the European Commission to market Sibnayal â„¢ for the treatment of distal renal tubular acidosis (dTRA). The approval makes it the first and only drug approved by the label for the treatment of dRTA in adults, adolescents and children aged one year and older.

  • Received Medicines & Healthcare products Regulatory Agency (MHRA) approval to market Sibnayal â„¢ in the UK for the treatment of dATR.

  • Obtained US Food and Drug Administration (FDA) acceptance of the company’s modified protocol for the company’s US pivotal Phase III trial on Sibnayal â„¢ for the treatment of dATR.

On corporate governance and financing

  • Carrying out a capital increase of 9.4 million euros to finance the continued clinical development of Sibnayal â„¢, its flagship product.

  • Strengthening of the management team with the appointment of Mr. Didier Laurens as CEO.

  • Define a new strategic vision, Advicenne 2.0, to maximize shareholder value. Under the new strategy, the first priority is to secure partnerships in Europe to generate commercial sales of Sibnayal â„¢ in dRTA. The second priority is to optimize the clinical development of Sibnayal â„¢ in the United States.

Key financial data

The financial results for the first half of 2021 are presented in accordance with IFRS rules. The results were approved on September 28, 2021 by the Board of Directors of the Company. The main financial data are presented in the tables below. The H1 2021 financial report is available on the Company’s website:

REVENUE STATEMENT (in thousands of euros)

June 30, 2021

June 30, 2020




Other exploitation products



Total income and other income



Operating Expenses


-9 334

Operating loss

-7 547

-7 715

Consolidated net income

-7 990


Earnings per share (€ / share)



Diluted earnings per share (€ / share)




June 30, 2021

December 31, 2020

Non-current assets


3 215

Current assets


20 789

of which cash and cash equivalents



Total assets



Total equity


3 272

Non-current liabilities

13 930

9 366

of which borrowings and financial debts

13 848


Current liabilities


11 367

of which borrowings and financial debts

of which trade payables

of which other current liabilities







Total responsibilities



CASH FLOWS (in thousands of euros)

June 30, 2021

June 30, 2020

Operating cash flow



of which cash flow

of which change in working capital

-7 185

-1 342



Cash flow from investing activities



Cash flow from financing activities

8 948

7 398

of which capital increase

of which change in loans and repayable advances




Change in cash



Checkout opening

Closing box



16 628

17 825

About Advicenna

Advicenne (Euronext: ADVIC) is a specialized pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its flagship product SibnayalMT (ADV 7103) has received marketing authorization for distal renal tubular acidosis in the EU and UK. ADV 7103 is currently in advanced stages of development in cystinuria in Europe and in dRTA and cystinuria in the United States. Based in Paris, Advicenne has been listed on the Euronext Paris stock exchange since 2017 and was cross-listed on the Euronext Brussels stock exchange in 2019.

For more information, see:

Forward-looking statements

This press release contains certain forward-looking statements relating to Advicenna’s business, which should not in themselves be regarded as historical facts. These statements include projections and estimates, and the assumptions on which they are based, as well as observations relating to operations, current projects, objectives, product development and future performance, and expectations regarding results. financial.

In some cases, forward-looking statements may be identified by words such as “could”, “should”, “could”, “expects”, “anticipates”, “believes”, “intends”, “Believes,” “aims,” ​​”targets,” or similar words. While management of Advicenna believes these forward-looking statements are reasonable, investors should be aware that they are subject to a number of risks and risks. known and unknown uncertainties and other factors which may cause actual results, performance or achievements to differ materially from future results, performance or achievements expressed or implied by these forward-looking statements. In particular, Advicenna’s expectations could be affected, among other things, by uncertainties related to the marketing and marketing of Advicenna’s products or by any other risk and uncertainty developed or identified in any public document filed by r Advicenne with the French financial markets. Authority (Financial Markets Authority (AMF)), including those listed in Chapter 4 “Risk factors” of its universal registration document, filed with the latter on December 22, 2020. Notwithstanding compliance with article 223-1 of the general regulations of the AMF (the information disclosed must be “accurate, precise and faithfully presented”), Advicenne disclaims any intention or obligation to update or publicly revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Comments are closed.